BELLICUM PHARMACEUTICALS INC's ticker is BLCM and the CUSIP is 079481107. A total of 96 filers reported holding BELLICUM PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 1.32 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $502,000 | +16.2% | 148,843 | +0.5% | 0.00% | 0.0% |
Q4 2018 | $432,000 | -73.3% | 148,115 | -43.6% | 0.00% | 0.0% |
Q3 2018 | $1,616,000 | +67.5% | 262,496 | +100.7% | 0.00% | 0.0% |
Q2 2018 | $965,000 | +74.8% | 130,786 | +55.4% | 0.00% | 0.0% |
Q1 2018 | $552,000 | -21.8% | 84,160 | +0.3% | 0.00% | 0.0% |
Q4 2017 | $706,000 | -26.2% | 83,921 | +1.3% | 0.00% | 0.0% |
Q3 2017 | $957,000 | +3.1% | 82,883 | +4.3% | 0.00% | 0.0% |
Q2 2017 | $928,000 | +110.4% | 79,471 | +122.3% | 0.00% | 0.0% |
Q1 2017 | $441,000 | -9.1% | 35,748 | +0.4% | 0.00% | 0.0% |
Q4 2016 | $485,000 | -27.8% | 35,608 | +5.5% | 0.00% | 0.0% |
Q3 2016 | $672,000 | +53.4% | 33,764 | 0.0% | 0.00% | 0.0% |
Q2 2016 | $438,000 | +284.2% | 33,764 | +177.9% | 0.00% | – |
Q1 2016 | $114,000 | -53.7% | 12,151 | 0.0% | 0.00% | – |
Q4 2015 | $246,000 | +39.0% | 12,151 | 0.0% | 0.00% | – |
Q3 2015 | $177,000 | -31.4% | 12,151 | 0.0% | 0.00% | – |
Q2 2015 | $258,000 | +35.1% | 12,151 | +47.2% | 0.00% | – |
Q1 2015 | $191,000 | – | 8,254 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
FRAZIER MANAGEMENT LLC | 1,051,441 | $7,760,000 | 1.61% |
X-Square Capital, LLC | 102,832 | $759,000 | 0.57% |
CORRADO ADVISORS, LLC | 78,945 | $582,000 | 0.35% |
Endurant Capital Management LP | 71,801 | $530,000 | 0.23% |
Baker Brothers Advisors | 4,093,447 | $30,210,000 | 0.23% |
KNOTT DAVID M | 76,653 | $566,000 | 0.21% |
L & S Advisors Inc | 83,125 | $613,000 | 0.10% |
DAFNA Capital Management LLC | 30,000 | $221,000 | 0.10% |
FARALLON CAPITAL MANAGEMENT LLC | 2,000,000 | $14,760,000 | 0.09% |
HARVEY CAPITAL MANAGEMENT INC | 31,200 | $230,000 | 0.09% |